anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

189,241-189,300 of 319,975

filter-aware
01
Slide 1
The phrase 'one-tract mind' is a pun on the gastrointestinal tract.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
02
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a stepped process diagram to link scientific focus to business outcomes.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a visual connection (lines) to link each executive to a set of company logos representing their past experience.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
06
Uses a Venn diagram to illustrate the intersection of three core business pillars.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a Gantt-style visualization to represent clinical trial progress.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
08
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
09
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
Includes anatomical comparison of normal vs. SBS GI tract.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses a medical illustration to show the digestive tract and the specific portion of the ileum removed in SBS patients.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
Uses a path-based diagram to illustrate the progression from diagnosis to long-term outcomes and patient experience.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses a biological process diagram to illustrate the therapeutic mechanism.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Uses a pyramid diagram to illustrate the patient population spectrum for SBS.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
15
The text 'Vurolenatide for short Bowel syndrome Regardless of pArental support requiremeNT' uses an acrostic-like emphasis on letters to spell VIBRANT.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
16
The title uses an acrostic-style emphasis on letters (V, B, R, A, N) which spells VBRAN, likely a branding or mnemonic device.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
17
The slide details a 4-group study design with varying dosages of medication vs placebo over a 28-day treatment period.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
18
The table displays N, sex, age, weight, race, ethnicity, and surgical status for placebo and three treatment arms.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
19
The chart compares placebo, 50 mg Q2W, 50 mg weekly, and 100 mg Q2W groups, highlighting percentage decreases relative to the placebo increase.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
20
The chart displays clinical trial data for 9Meters Biopharma, showing efficacy of the 50mg Q2W dosage.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
21
The chart displays clinical trial data for three small cohorts (n=3 each).9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
22
The slide highlights the efficacy of the 50 mg Q2W dose compared to other cohorts.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
23
TSO likely refers to a specific clinical biomarker or symptom score.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Traction1 hit
24
The chart illustrates the 'stacking effect' (undesirable accumulation) in the 50 mg weekly and 100 mg Q2W groups, contrasting them with the 50 mg Q2W group which stays within the target range.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
25
The slide highlights a secondary endpoint result for a specific subset of patients.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
26
The table displays counts of specific adverse events (Nausea, Vomiting, etc.) across four study arms.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
27
The slide uses checkmarks to denote key achievements/findings.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
28
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Next Steps1 hit
29
9 Meters Biopharma | Investor Presentation Deck | 30 slides9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations Beat · Next Steps1 hit
30
This is a contact/closing slide.9 Meters Biopharma | Investor Presentation Deck | 30 slides · 9 Meters Biopharma
Pitch deck Investor relations 1 hit
01
Slide 1
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
02
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
03
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
04
The slide uses a split layout with a left-hand column for quantitative KPIs and a right-hand column for qualitative business highlights.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble Origins1 hit
05
The H1 2021 chart shows a very high concentration in Germany (94%), while H1 2022 shows significant diversification.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Humble OriginsLoop · Before After1 hit
06
ads-tec Energy | Investor Presentation Deck | 32 slidesads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
07
Contains a typo in 'Reserach and development expenses'.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
08
Values are in kEUR.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
09
The table displays financial figures in kEUR, comparing two half-year periods.ads-tec Energy | Investor Presentation Deck | 32 slides · ads-tec Energy
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
19
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Satisfaction1 hit
20
Includes a breakdown of growth-related costs impacting margins.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Satisfaction1 hit
21
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Satisfaction1 hit
22
Includes segment-level breakdown for Zegna and Thom Browne.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Satisfaction1 hit
23
Includes a callout box explaining the impact of put option liability on Thom Browne stake.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Satisfaction1 hit
24
The slide explains the decrease in cash surplus from (145) to (103) million euros.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Action1 hit
25
The slide compares Capex (1H22 vs 1H21) and Trade Working Capital (Jun-2022 vs Dec-2022).Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Action1 hit
26
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
27
The slide uses a circular icon-based layout to categorize assumptions by geography, product line, and channel.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
28
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations Beat · Action1 hit
29
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
30
The table tracks store counts across three dates: June 30, 2022; Dec 31, 2021; and June 30, 2021.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
31
Standard financial reporting disclosure slide.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
32
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
33
Includes detailed footnotes explaining specific adjustments made to arrive at Adjusted EBIT.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
34
Includes detailed footnotes explaining specific financial adjustments.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
35
Includes detailed footnotes explaining specific adjustments like impairment, business combination costs, and disposals.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
36
The slide provides a reconciliation of non-IFRS financial measures, specifically Net Financial Indebtedness.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
37
The table shows the reconciliation from working capital to trade working capital.Zegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
38
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit
39
Zegna | Results Presentation Deck | 39 slidesZegna | Results Presentation Deck | 39 slides · Ermenegildo Zegna Group
Conference presentation Investor relations 1 hit